FDA Advisory Panel Votes to Allow Claim Regarding Jardiance Cardiovascular  Events

FDA Advisory Panel Votes to Allow Claim Regarding Jardiance Cardiovascular Events

A US Food and Drug Administration (FDA) advisory panel has narrowly voted to approve a Jardiance claim that the drug can decrease the risk of cardiovascular death. Jardiance (empagliflozin), an…

More in Health >
FDA Explores Invokana Increasing the Risk for Amputation?

FDA Explores Invokana Increasing the Risk for Amputation?

The FDA has issued a recent safety communication warning the public of the famous diabetes medicine canagliflozin.¬†The safety issue was in relation to an ongoing ¬†interim clinical trial that found…

More in Health >